Stefan von Holtzbrinck voting rights in Springer Nature drop to 50.63% from 86.60%
Bitget2026/10/08 08:01Stefan von Holtzbrinck cut his total voting rights stake in Springer Nature to 50.63% from 86.6%. The move followed the end of an acting-in-concert agreement on Oct. 4, 2026. Voting rights attributed from Springer Science+Business Media Galileo Participation fell by 71,538,141 shares, or 35.97%. Voting rights attributed via GvH Vermögensverwaltungsgesellschaft XXXIII remained 100,700,053 shares, or 50.63%. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Springer Nature AG & Co. KgaA published the original content used to generate this news brief via EQS News (Ref. ID: PVR_2412074_de) on October 08, 2026, and is solely responsible for the information contained therein.
- Stefan von Holtzbrinck cut his total voting rights stake in Springer Nature to 50.63% from 86.6%.
- The move followed the end of an acting-in-concert agreement on Oct. 4, 2026.
- Voting rights attributed from Springer Science+Business Media Galileo Participation fell by 71,538,141 shares, or 35.97%.
- Voting rights attributed via GvH Vermögensverwaltungsgesellschaft XXXIII remained 100,700,053 shares, or 50.63%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.

Canaccord Genuity: Lowers Oklo's target price to $66

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
